ES2538551R2 - Composición Oftálmica para la corrección de la presbicia - Google Patents

Composición Oftálmica para la corrección de la presbicia Download PDF

Info

Publication number
ES2538551R2
ES2538551R2 ES201301177A ES201301177A ES2538551R2 ES 2538551 R2 ES2538551 R2 ES 2538551R2 ES 201301177 A ES201301177 A ES 201301177A ES 201301177 A ES201301177 A ES 201301177A ES 2538551 R2 ES2538551 R2 ES 2538551R2
Authority
ES
Spain
Prior art keywords
presbyopia
correction
ophthalmic composition
pilocarpine
bromfenac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES201301177A
Other languages
English (en)
Other versions
ES2538551B1 (es
ES2538551A2 (es
Inventor
José Vicente RODRIGUEZ HERNANDEZ
Humberto CARRERAS DIAZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HUMBERTO CARRERAS DIAZ
Original Assignee
Eurocanarias Oftalmologica Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eurocanarias Oftalmologica Sl filed Critical Eurocanarias Oftalmologica Sl
Priority to ES201301177A priority Critical patent/ES2538551B1/es
Priority to US14/225,704 priority patent/US9987254B2/en
Priority to EP14169660.9A priority patent/EP2886113A1/en
Priority to BR102014021743A priority patent/BR102014021743A2/pt
Priority to JP2014208945A priority patent/JP2015120680A/ja
Priority to PCT/ES2014/000200 priority patent/WO2015092087A1/es
Publication of ES2538551A2 publication Critical patent/ES2538551A2/es
Publication of ES2538551R2 publication Critical patent/ES2538551R2/es
Application granted granted Critical
Publication of ES2538551B1 publication Critical patent/ES2538551B1/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composición oftálmica para la corrección de la presbicia.#Consistente en pilocarpina al 2%, caracterizada por estar diluida al 1% con solución salina balanceada estéril (BSS), obteniendo una pilocarpina al 1% (2.5 ml) + bromfenaco, 1.8 mgrs de bromfenaco (2.5 ml) + solución salina balanceada estéril (BSS) (2.5 ml), obteniéndose en total un colirio de 7.5 ml, pudiendo obtenerse también una pilocarpina al 1,5% y al 2%.
ES201301177A 2013-12-20 2013-12-20 Composición Oftálmica para la corrección de la presbicia Active ES2538551B1 (es)

Priority Applications (6)

Application Number Priority Date Filing Date Title
ES201301177A ES2538551B1 (es) 2013-12-20 2013-12-20 Composición Oftálmica para la corrección de la presbicia
US14/225,704 US9987254B2 (en) 2013-12-20 2014-03-26 Ophthalmic composition for correcting presbyopia
EP14169660.9A EP2886113A1 (en) 2013-12-20 2014-05-23 Ophthalmic composition for the correction of presbyopia
BR102014021743A BR102014021743A2 (pt) 2013-12-20 2014-09-02 composição oftálmica para a correção de presbiopia
JP2014208945A JP2015120680A (ja) 2013-12-20 2014-10-10 老視の矯正のための眼用組成物
PCT/ES2014/000200 WO2015092087A1 (es) 2013-12-20 2014-12-02 Composición oftálmica para la corrección de la presbicia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201301177A ES2538551B1 (es) 2013-12-20 2013-12-20 Composición Oftálmica para la corrección de la presbicia

Publications (3)

Publication Number Publication Date
ES2538551A2 ES2538551A2 (es) 2015-06-22
ES2538551R2 true ES2538551R2 (es) 2015-07-07
ES2538551B1 ES2538551B1 (es) 2016-01-13

Family

ID=50774692

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201301177A Active ES2538551B1 (es) 2013-12-20 2013-12-20 Composición Oftálmica para la corrección de la presbicia

Country Status (6)

Country Link
US (1) US9987254B2 (es)
EP (1) EP2886113A1 (es)
JP (1) JP2015120680A (es)
BR (1) BR102014021743A2 (es)
ES (1) ES2538551B1 (es)
WO (1) WO2015092087A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY168643A (en) 2011-09-20 2018-11-27 Allergan Inc Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism
US11452732B2 (en) * 2015-09-05 2022-09-27 Randal Davis Homogeneous ophthalmic composition
BR112019002967A2 (pt) * 2016-08-19 2019-05-14 Orasis Pharmaceuticals Ltd. composição farmacêutica oftálmica, métodos de corrigir presbiopia, de reduzir o tamanho de uma pupila, de induzir miose, de aumentar a profundidade de campo, de diminuir a grandeza de aberrações de ordem superior e de melhorar a acuidade visual não corrigida de perto e de longe, implante, e, kit.
EP3681500B1 (en) * 2018-04-24 2022-03-23 Allergan, Inc. Use of pilocarpine hydrochloride for the treatment of presbyopia
CA3131264A1 (en) * 2019-03-04 2020-09-10 Eyenovia, Inc. Methods and devices for delivering pilocarpine to the eye as a micro-dose stream of droplets
MX2020012116A (es) * 2020-11-12 2022-08-09 Cesar Alejandro Sanchez Galeana Composicion oftalmologica sinergica en dosis de baja concentracion eficaz en la prevencion, control y erradicacion de la presbicia.
ES2925732A1 (es) * 2021-04-06 2022-10-19 Presbycarrod Drops S L Composición oftálmica

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2787991B1 (fr) 1998-12-31 2001-05-25 Medicale De Prec S M P Sa Soc Dispositif pour traiter la presbytie ou autre affection oculaire
WO2000074600A1 (en) 1999-06-07 2000-12-14 Ras Holding Corporation Improved scleral prosthesis for treatment of presbyopia and other eye disorders
DE60230173D1 (de) 2001-10-19 2009-01-15 Bausch & Lomb Presbyopiekorrektur
ES2304824B1 (es) 2005-11-10 2009-07-06 Fundacio Privada Catalana D'oftalmologia Grimaldi Juego de lentillas mascara para sistema laser de tratamiento de la presbicia.
ES2329161T3 (es) * 2006-12-18 2009-11-23 Jorge Luis Benozzi Composiciones oftalmicas de estimulantes parasimpaticos y antiinflamatorios para su uso en el tratamiento de la presbicia.
ES2337748B1 (es) 2007-01-03 2011-02-14 Belver Inmaculada Zamora Sistema de generacion y almacenamiento, a bordo, de hidrogeno y oxigeno procedentes de la energia de frenado regenerativo de vehiculos.
WO2010135731A1 (en) * 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
MY168643A (en) * 2011-09-20 2018-11-27 Allergan Inc Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism
WO2013055856A1 (en) 2011-10-12 2013-04-18 Bausch & Lomb Incorporated Ocular composition containing bromfenac with increased bioavailability
US10507245B2 (en) * 2012-07-19 2019-12-17 Luis Felipe Vejarano Restrepo Ophthalmic formulation and method for ameliorating presbyopia

Also Published As

Publication number Publication date
US9987254B2 (en) 2018-06-05
EP2886113A1 (en) 2015-06-24
WO2015092087A1 (es) 2015-06-25
ES2538551B1 (es) 2016-01-13
BR102014021743A2 (pt) 2020-04-07
ES2538551A2 (es) 2015-06-22
US20150174105A1 (en) 2015-06-25
JP2015120680A (ja) 2015-07-02

Similar Documents

Publication Publication Date Title
ES2538551R2 (es) Composición Oftálmica para la corrección de la presbicia
BR112014030330A2 (pt) lentes oftálmicas levando em consideração a lateralidade do usuário
GT201600007A (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
BR112017012344A2 (pt) anticorpos anti-c10orf54 e usos dos mesmos
MX2023003124A (es) Composiciones farmaceuticas oftalmicas y usos que se relacionan a las mismas.
WO2015026601A3 (en) Dithiol mucolytic agents
MY171920A (en) Prevention and treatment of ocular conditions
EA201591426A1 (ru) Соединения и их применения для модуляции гемоглобина
EA201591427A1 (ru) Соединения и их применения для модуляции гемоглобина
WO2012103186A3 (en) Androgen composition for treating an opthalmic condition
EA201492040A1 (ru) Бициклически замещённые урацилы и их применение
WO2016022776A3 (en) Increasing atoh1 life to drive sensorineural hair cell differentiantion
MX2016004378A (es) Sistema de diagnostico y metodo de diagnostico.
CL2017002427A1 (es) Producción de ácido ribonucleico libre de células.
EP4268843A3 (en) Improved il-6 antibodies
BR112013030554A2 (pt) forma cristalina de ciclosporina a, métodos de preparação e métodos para uso da mesma
BR112015019008A8 (pt) Par de lentes oftálmicas progressivas
MX2013005666A (es) Lentes de contacto con efecto de halo.
HUE048829T2 (hu) Multifokális szemlencse, amelyet a szemben vagy a szemén kell viselni
MX2016015211A (es) Formulaciones topicas y usos de las mismas.
BR112015009476A2 (pt) dispositivo de alívio de pressão tendo uma linha de abertura definida a laser
EA201301332A1 (ru) ОФТАЛЬМОЛОГИЧЕСКИЙ ПРЕПАРАТ, СОДЕРЖАЩИЙ АНАЛОГ PGF2α
CY1124538T1 (el) Χρηση prg4 για τη βελτιωση της δυναμικης οπτικης οξυτητας και εκτροπων υψηλοτερης ταξης
EA201791611A1 (ru) Лечение пациентов детского возраста с сахарным диабетом 2 типа с помощью ликсисенатида
RU2016136333A (ru) Фармакологическая офтальмологическая композиция, используемая в коррекции пресбиопии, и ее введение

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2538551

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20160113

PC2A Transfer of patent

Owner name: HUMBERTO CARRERAS DIAZ

Effective date: 20180418